SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

Core Insights - Sera Prognostics Inc. will report its fourth quarter and fiscal year 2025 financial results on March 18, 2026, followed by a conference call to discuss operational highlights and financial results [1] - The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information [1] - The PreTRM® Test is a key product that predicts the risk of spontaneous preterm birth, allowing for earlier interventions [1] Company Overview - Sera Prognostics is dedicated to enhancing the lives of women and babies through precision pregnancy care [1] - The company is headquartered in Salt Lake City, Utah, and aims to reduce healthcare delivery costs by providing early pregnancy information [1] - Sera has a robust pipeline of diagnostic tests aimed at predicting preterm birth risk and other pregnancy complications [1] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [1] - The 2025 March of Dimes Report Card indicates that the U.S. has received a D+ grade for preterm birth for four consecutive years, marking the longest stretch of the lowest grade in history [1] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [1] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test for predicting spontaneous preterm birth in asymptomatic singleton pregnancies [1] - It analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify at-risk women between weeks 18 and 20 of pregnancy [1] - The test enables more informed clinical decisions based on individual risk assessments [1]